Numinus Wellness Past Earnings Performance
Past criteria checks 0/6
Numinus Wellness's earnings have been declining at an average annual rate of -30.6%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 71.5% per year.
Key information
-30.6%
Earnings growth rate
-1.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 71.5% |
| Return on equity | -550.7% |
| Net Margin | -113.5% |
| Last Earnings Update | 31 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Numinus Wellness makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 May 24 | 22 | -26 | 24 | 0 |
| 29 Feb 24 | 23 | -27 | 28 | 0 |
| 30 Nov 23 | 23 | -28 | 30 | 1 |
| 31 Aug 23 | 23 | -30 | 32 | 1 |
| 31 May 23 | 19 | -44 | 33 | 2 |
| 28 Feb 23 | 14 | -45 | 31 | 2 |
| 30 Nov 22 | 11 | -46 | 31 | 2 |
| 31 Aug 22 | 6 | -45 | 27 | 2 |
| 31 May 22 | 3 | -28 | 22 | 2 |
| 28 Feb 22 | 3 | -26 | 20 | 2 |
| 30 Nov 21 | 2 | -22 | 17 | 2 |
| 31 Aug 21 | 2 | -19 | 14 | 1 |
| 31 May 21 | 1 | -14 | 12 | 1 |
| 28 Feb 21 | 1 | -13 | 9 | 0 |
| 30 Nov 20 | 1 | -11 | 8 | 0 |
| 31 Aug 20 | 1 | -10 | 7 | 0 |
| 31 May 20 | 1 | -10 | 6 | 0 |
| 29 Feb 20 | 0 | -8 | 6 | 0 |
| 30 Nov 19 | 0 | -7 | 5 | 0 |
| 31 Aug 19 | 0 | -7 | 5 | 0 |
| 31 Aug 18 | 3 | -3 | 3 | 0 |
Quality Earnings: LR23 is currently unprofitable.
Growing Profit Margin: LR23 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LR23 is unprofitable, and losses have increased over the past 5 years at a rate of 30.6% per year.
Accelerating Growth: Unable to compare LR23's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LR23 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: LR23 has a negative Return on Equity (-550.68%), as it is currently unprofitable.